These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 33705871)

  • 1. Targeting the acetylation signaling pathway in cancer therapy.
    Dang F; Wei W
    Semin Cancer Biol; 2022 Oct; 85():209-218. PubMed ID: 33705871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM; Roth DM; Marchal C; Bouchecareilh M
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonhistone protein acetylation as cancer therapy targets.
    Singh BN; Zhang G; Hwa YL; Li J; Dowdy SC; Jiang SW
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):935-54. PubMed ID: 20553216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging roles of HDACs and their therapeutic implications in cancer.
    Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
    Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC Inhibitors.
    Olzscha H; Bekheet ME; Sheikh S; La Thangue NB
    Methods Mol Biol; 2016; 1436():281-303. PubMed ID: 27246222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs.
    Schuetze KB; McKinsey TA; Long CS
    J Mol Cell Cardiol; 2014 May; 70():100-7. PubMed ID: 24631770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
    Wahi A; Jain P; Sinhari A; Jadhav HR
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in understanding the roles of plant HAT and HDAC in non-histone protein acetylation and deacetylation.
    Zhang Z; Zeng Y; Hou J; Li L
    Planta; 2024 Sep; 260(4):93. PubMed ID: 39264431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases.
    Dekker FJ; van den Bosch T; Martin NI
    Drug Discov Today; 2014 May; 19(5):654-60. PubMed ID: 24269836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assay for inhibitory activity of histone deacetylase].
    Yoshida M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylation of non-histone proteins modulates cellular signalling at multiple levels.
    Spange S; Wagner T; Heinzel T; Krämer OH
    Int J Biochem Cell Biol; 2009 Jan; 41(1):185-98. PubMed ID: 18804549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
    Li Z; Zhu WG
    Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of protein turnover by acetyltransferases and deacetylases.
    Sadoul K; Boyault C; Pabion M; Khochbin S
    Biochimie; 2008 Feb; 90(2):306-12. PubMed ID: 17681659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of protein acetylation in carcinogenesis and targeted drug discovery.
    Yang J; Song C; Zhan X
    Front Endocrinol (Lausanne); 2022; 13():972312. PubMed ID: 36171897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
    Langley B; Gensert JM; Beal MF; Ratan RR
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of histone deacetylases inhibitors in glioblastoma.
    Chen R; Zhang M; Zhou Y; Guo W; Yi M; Zhang Z; Ding Y; Wang Y
    J Exp Clin Cancer Res; 2020 Jul; 39(1):138. PubMed ID: 32682428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
    Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
    Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.